The increasing complexity of cancer chemotherapy makes it mandatory that pharmacists be familiar with these highly toxic agents. This column focuses on the commercially available and investigational agents used to treat malignant diseases and reviews issues related to the preparation, dispensing, and administration of cancer chemotherapy.
Get full access to this article
View all access options for this article.
References
1.
NCCN non-Hodgkins practice guidelines.The Complete Library of NCCN Oncology Practice Guidelines [CD-ROM]. Version 1. Rockledge, PA: National Comprehensive Cancer Network; 2003.
2.
SchiavoneE.M., De SimoneM., PalmieriS.Fludarabine plus cyclophosphamide for the treatment of advanced chronic lymphocytic leukemia.Eur J Haematol.2003; 71: 23–8.
3.
EuckerJ., SchilleC., SchmidP.The combination of fludarabine and cyclophosphamide results in a high remission rate with moderate toxicity in low-grade non-Hodgkin's lymphomas.Anticancer Drugs.2002; 13: 907–13.
4.
O'BrienS., KantarjianH.M., CartesJ.Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia.J Clin Oncol.2001; 19: 1414–20.
5.
HallekM., SchmittB., WilhelmM.Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukemia (CLL): Results of a phase II study of the German CLL Study Group.Br J Haematol.2001; 114: 342–8.
6.
LossosI.S., PaltielO., PolliackA.Salvage chemotherapy using a combination of fludarabine and cyclophosphamide for refractory or relapsing indolent and aggressive non-Hodgkin's lymphomas.Leukemia Lymphoma.1999; 33: 155–60.
7.
WierdaW., Garcia-ManeroG., O'BrienS.Molecular remissions in patients with relapsed or refractory CLL treated with combined fludarabine, cyclophosphamide, and rituximab [abstract 2335].Proc Am Soc Clin Oncol.2003; 22.
8.
Garcia-ManeroG., O'BrienS., CortesJ.Update of results of the combination of fludarabine, cyclophosphamide and rituximab for previously treated patients with chronic lymphocytic leukemia (CLL) [abstract 2650].Blood.2001; 98.
9.
WierdaW., O'BrienS., AlbitarM.Combined fludarabine, cyclophosphamide, and rituximab achieves a high complete remission rate as initial treatment for chronic lymphocytic leukemia [abstract 3210].Blood.2001; 98.
10.
Rituxan (rituximab) [package information].South San Francisco, CA: Genentech, Inc.; February 2002.
11.
HeskethP.J., KrisM.G., GrunbergS.M.Proposal for classifying the acute emetogenicity of cancer chemotherapy.J Clin Oncol.1997; 15: 103–9.
12.
American Society of Health-System Pharmacists.ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery.Am J Health Syst Pharm.1999; 56: 729–64.
13.
GrallaR.J., OsobaD., KrisM.G.Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines.J Clin Oncol.1999; 17: 2971–94.
14.
NCCN antiemesis practice guidelines.The Complete Library of NCCN Oncology Practice Guidelines [CD-ROM] Version 1. Rockledge, PA: National Comprehensive Cancer Network; 2003.
15.
StillwellT.J., BensonR.C.Cyclophosphamide-induced hemorrhagic cystitis. A review of 100 patients.Cancer.1988; 61: 451–7.
16.
OzerH., ArmitageJ.O., BennettC.L.2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines.J Clin Oncol.2000; 18: 3558–85.
LymanG.H., KudererN., GreeneJ.The economics of febrile neutropenia: implications for the use of colony-stimulating factors.Eur J Cancer.1998; 34: 1857–64.
19.
LymanG.H., BalducciL.Update of the economic analyses of the use of colony-stimulating factors.Curr Opin Hematol.1999; 6: 145–51.
20.
LymanG.H.A novel approach to maintain planned dose chemotherapy on time: A decision-making tool to improve patient care.Eur J Cancer.2000; 36(Suppl 11): S15–S21.
21.
KintzelP.E., DorrR.T.Anticancer drug renal toxicity and elimination: Dosing guidelines for altered renal function.Cancer Treat Rev.1995; 21: 33–64.
22.
PattersonW.P., ReamsG.P.Renal and electrolyte abnormalities due to chemotherapy. In: The Chemotherapy Sourcebook.3rd ed.PerryM.C., ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2001, 494–504.
23.
KingP.D., PerryM.C.Hepatotoxicity of chemotherapeutic and oncologic agents.Gastroenterol Clin North Am.1995; 24: 969–89.
